Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Perceived versus calculated HIV risk: Implications for Pre-exposure prophylaxis uptake in a randomized trial of men who have sex with men.

Blumenthal J, Jain S, Mulvihill E, Sun S, Hanashiro M, Ellorin E, Graber S, Haubrich R, Morris S.

J Acquir Immune Defic Syndr. 2018 Oct 29. doi: 10.1097/QAI.0000000000001888. [Epub ahead of print]

PMID:
30422909
2.

Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study among Individuals at Risk for HIV.

Milam J, Jain S, Dubé MP, Daar ES, Sun X, Corado K, Ellorin E, Blumenthal J, Haubrich R, Moore DJ, Morris SR; CCTG Team.

J Acquir Immune Defic Syndr. 2018 Oct 10. doi: 10.1097/QAI.0000000000001885. [Epub ahead of print]

PMID:
30334877
3.

Analysis of drug-drug interactions among patients receiving antiretroviral regimens using data from a large open-source prescription database.

Patel N, Borg P, Haubrich R, McNicholl I.

Am J Health Syst Pharm. 2018 Aug 1;75(15):1132-1139. doi: 10.2146/ajhp170613. Epub 2018 Jun 14.

PMID:
29903710
4.

Randomized Trial of a Health Coaching Intervention to Enhance Retention in Care: California Collaborative Treatment Group 594.

Corado K, Jain S, Morris S, Dube MP, Daar ES, He F, Aldous JL, Sitapati A, Haubrich R, Milam J, Karris MY.

AIDS Behav. 2018 Aug;22(8):2698-2710. doi: 10.1007/s10461-018-2132-3.

PMID:
29725790
5.

Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults.

Kearney MF, Spindler J, Wiegand A, Shao W, Haubrich R, Riddler S, Lalama CM, Hughes MD, Coffin JM, Mellors JW.

PLoS One. 2018 Jan 25;13(1):e0190438. doi: 10.1371/journal.pone.0190438. eCollection 2018.

6.

Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.

Moore DJ, Jain S, Dubé MP, Daar ES, Sun X, Young J, Corado K, Ellorin E, Milam J, Collins D, Blumenthal J, Best BM, Anderson P, Haubrich R, Morris SR.

Clin Infect Dis. 2018 May 2;66(10):1566-1572. doi: 10.1093/cid/cix1055.

PMID:
29228144
7.

Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.

Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS Jr; RESCUE and ACTG A5348 study investigators.

Liver Int. 2018 Jun;38(6):1010-1021. doi: 10.1111/liv.13616. Epub 2017 Dec 5.

PMID:
29091342
8.

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.

Mollan KR, Tierney C, Hellwege JN, Eron JJ, Hudgens MG, Gulick RM, Haubrich R, Sax PE, Campbell TB, Daar ES, Robertson KR, Ventura D, Ma Q, Edwards DRV, Haas DW; AIDS Clinical Trials Group.

J Infect Dis. 2017 Sep 1;216(5):554-564. doi: 10.1093/infdis/jix248.

9.

Digitizing Medicines for Remote Capture of Oral Medication Adherence Using Co-encapsulation.

Browne SH, Peloquin C, Santillo F, Haubrich R, Muttera L, Moser K, Savage GM, Benson CA, Blaschke TF.

Clin Pharmacol Ther. 2018 Mar;103(3):502-510. doi: 10.1002/cpt.760. Epub 2017 Sep 19.

10.

Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice.

Drozd DR, Saag MS, Westfall AO, Mathews WC, Haubrich R, Boswell SL, Cole SR, Porter D, Kitahata MM, Juday T, Rosenblatt L; CFAR Network of Integrated Clinical Systems (CNICS).

Medicine (Baltimore). 2017 Apr;96(14):e6275. doi: 10.1097/MD.0000000000006275.

11.

HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen.

Karris MY, Jain S, Day TR, Pérez-Santiago J, Goicoechea M, Dubé MP, Sun X, Spina C, Daar ES, Haubrich RH, Morris S; California Collaborative Treatment Group (CCTG) 589 Study Team.

HIV Clin Trials. 2017 Mar;18(2):67-74. doi: 10.1080/15284336.2017.1282578. Epub 2017 Jan 30.

12.

Impact of pre-adapted HIV transmission.

Carlson JM, Du VY, Pfeifer N, Bansal A, Tan VY, Power K, Brumme CJ, Kreimer A, DeZiel CE, Fusi N, Schaefer M, Brockman MA, Gilmour J, Price MA, Kilembe W, Haubrich R, John M, Mallal S, Shapiro R, Frater J, Harrigan PR, Ndung'u T, Allen S, Heckerman D, Sidney J, Allen TM, Goulder PJ, Brumme ZL, Hunter E, Goepfert PA.

Nat Med. 2016 Jun;22(6):606-13. doi: 10.1038/nm.4100. Epub 2016 May 16.

13.

Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.

Karris MY, Jain S, Bowman VQ, Rieg G, Goicoechea M, Dube MP, Kerkar S, Kemper C, Diamond C, Sun X, Daar ES, Haubrich RH, Morris S; California Collaborative Treatment Group (CCTG) 589 Study Team.

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):e48-50. doi: 10.1097/QAI.0000000000000990. No abstract available.

14.

Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.

Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, John Gill M, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, Del Amo J, Moreno S, Rodríguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Pérez-Hoyos S, Jarrin I, Guest JL, D'Arminio Monforte A, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hernán MA; Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Clinical Systems, and the HIV-CAUSAL Collaboration.

Int J Epidemiol. 2016 Dec 1;45(6):2038-2049. doi: 10.1093/ije/dyv295.

15.

Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression.

Paris RM, Petrovas C, Ferrando-Martinez S, Moysi E, Boswell KL, Archer E, Yamamoto T, Ambrozak D, Casazza JP, Haubrich R, Connors M, Ake J, Kim JH, Koup RA.

PLoS One. 2015 Dec 17;10(12):e0144767. doi: 10.1371/journal.pone.0144767. eCollection 2015.

16.

HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial.

Tashima KT, Smeaton LM, Fichtenbaum CJ, Andrade A, Eron JJ, Gandhi RT, Johnson VA, Klingman KL, Ritz J, Hodder S, Santana JL, Wilkin T, Haubrich RH; A5241 Study Team.

Ann Intern Med. 2015 Dec 15;163(12):908-17. doi: 10.7326/M15-0949. Epub 2015 Nov 24.

17.

Randomized Controlled Trial of an Internet Application to Reduce HIV Transmission Behavior Among HIV Infected Men Who have Sex with Men.

Milam J, Morris S, Jain S, Sun X, Dubé MP, Daar ES, Jimenez G, Haubrich R; CCTG 592 Team.

AIDS Behav. 2016 Jun;20(6):1173-1181. doi: 10.1007/s10461-015-1215-7.

18.

High Prevalence of Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on Antiretroviral Therapy.

Innes S, Abdullah KL, Haubrich R, Cotton MF, Browne SH.

Pediatr Infect Dis J. 2016 Jan;35(1):e1-7. doi: 10.1097/INF.0000000000000927.

19.

Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy.

Massanella M, Gianella S, Schrier R, Dan JM, Pérez-Santiago J, Oliveira MF, Richman DD, Little SJ, Benson CA, Daar ES, Dube MP, Haubrich RH, Smith DM, Morris SR.

Sci Rep. 2015 Aug 24;5:13179. doi: 10.1038/srep13179.

20.

Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity.

Tashima KT, Mollan KR, Na L, Gandhi RT, Klingman KL, Fichtenbaum CJ, Andrade A, Johnson VA, Eron JJ, Smeaton L, Haubrich RH.

HIV Clin Trials. 2015 Aug;16(4):147-56. doi: 10.1179/1945577115Y.0000000001. Epub 2015 Jul 27.

21.

Genital Cytomegalovirus Replication Predicts Syphilis Acquisition among HIV-1 Infected Men Who Have Sex with Men.

Gianella S, Smith DM, Daar ES, Dube MP, Lisco A, Vanpouille C, Margolis L, Haubrich RH, Morris SR.

PLoS One. 2015 Jun 10;10(6):e0130410. doi: 10.1371/journal.pone.0130410. eCollection 2015.

22.

Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols.

Moore CB, Verma A, Pendergrass S, Verma SS, Johnson DH, Daar ES, Gulick RM, Haubrich R, Robbins GK, Ritchie MD, Haas DW.

Open Forum Infect Dis. 2015 Jan 9;2(1):ofu113. doi: 10.1093/ofid/ofu113. eCollection 2015 Jan.

23.

Knowledge is Power! Increased Provider Knowledge Scores Regarding Pre-exposure Prophylaxis (PrEP) are Associated with Higher Rates of PrEP Prescription and Future Intent to Prescribe PrEP.

Blumenthal J, Jain S, Krakower D, Sun X, Young J, Mayer K, Haubrich R; CCTG 598 Team.

AIDS Behav. 2015 May;19(5):802-10. doi: 10.1007/s10461-015-0996-z.

24.

Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure.

Fisher RG, Smith DM, Murrell B, Slabbert R, Kirby BM, Edson C, Cotton MF, Haubrich RH, Kosakovsky Pond SL, Van Zyl GU.

J Clin Virol. 2015 Jan;62:48-53. doi: 10.1016/j.jcv.2014.11.014. Epub 2014 Nov 20.

25.

Antiretroviral therapy in the elite controller: justified or premature?

Karris MY, Haubrich RH.

J Infect Dis. 2015 Jun 1;211(11):1689-91. doi: 10.1093/infdis/jiu812. Epub 2014 Dec 15. No abstract available.

PMID:
25512628
26.

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.

Lehmann DS, Ribaudo HJ, Daar ES, Gulick RM, Haubrich RH, Robbins GK, de Bakker PI, Haas DW, McLaren PJ.

Pharmacogenet Genomics. 2015 Feb;25(2):51-9. doi: 10.1097/FPC.0000000000000106.

27.

Will risk compensation accompany pre-exposure prophylaxis for HIV?

Blumenthal J, Haubrich RH.

Virtual Mentor. 2014 Nov 1;16(11):909-15. doi: 10.1001/virtualmentor.2014.16.11.stas1-1411. No abstract available.

28.

Changes in metabolic syndrome status after initiation of antiretroviral therapy.

Krishnan S, Schouten JT, Atkinson B, Brown TT, Wohl DA, McComsey GA, Glesby MJ, Shikuma C, Haubrich R, Jacobson DL.

J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):73-80. doi: 10.1097/QAI.0000000000000397.

29.

Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.

Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS.

Clin Infect Dis. 2014 Sep 15;59(6):888-96. doi: 10.1093/cid/ciu367. Epub 2014 May 19.

30.

Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment.

Gianella S, Massanella M, Richman DD, Little SJ, Spina CA, Vargas MV, Lada SM, Daar ES, Dube MP, Haubrich RH, Morris SR, Smith DM; California Collaborative Treatment Group 592 Team.

J Virol. 2014 Jul;88(14):7818-27. doi: 10.1128/JVI.00831-14. Epub 2014 Apr 30.

31.

Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.

Beliakova-Bethell N, Jain S, Woelk CH, Witt MD, Sun X, Lada SM, Spina CA, Goicoechea M, Rought SE, Haubrich R, Dubé MP.

Antiviral Res. 2014 Jul;107:42-9. doi: 10.1016/j.antiviral.2014.04.005. Epub 2014 Apr 24.

32.

HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.

Achenbach CJ, Buchanan AL, Cole SR, Hou L, Mugavero MJ, Crane HM, Moore RD, Haubrich RH, Gopal S, Eron JJ, Hunt PW, Rodriguez B, Mayer K, Saag MS, Kitahata MM; Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS).

Clin Infect Dis. 2014 Jun;58(11):1599-606. doi: 10.1093/cid/ciu076. Epub 2014 Feb 12.

33.

Differential escape patterns within the dominant HLA-B*57:03-restricted HIV Gag epitope reflect distinct clade-specific functional constraints.

Payne RP, Branch S, Kløverpris H, Matthews PC, Koofhethile CK, Strong T, Adland E, Leitman E, Frater J, Ndung'u T, Hunter E, Haubrich R, Mothe B, Edwards A, Riddell L, Chen F, Harrigan PR, Brumme ZL, Mallal S, John M, Jooste JP, Shapiro R, Deeks SG, Walker BD, Brander C, Landis C, Carlson JM, Prado JG, Goulder PJ.

J Virol. 2014 May;88(9):4668-78. doi: 10.1128/JVI.03303-13. Epub 2014 Feb 5.

34.

Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection.

Boswell KL, Paris R, Boritz E, Ambrozak D, Yamamoto T, Darko S, Wloka K, Wheatley A, Narpala S, McDermott A, Roederer M, Haubrich R, Connors M, Ake J, Douek DC, Kim J, Petrovas C, Koup RA.

PLoS Pathog. 2014 Jan 30;10(1):e1003853. doi: 10.1371/journal.ppat.1003853. eCollection 2014 Jan.

35.

Factors associated with high transmission risk and detectable plasma HIV RNA in HIV-infected MSM on ART.

Blumenthal J, Haubrich R, Jain S, Sun X, Dube M, Daar E, Milam J, Morris S.

Int J STD AIDS. 2014 Sep;25(10):734-41. doi: 10.1177/0956462413518500. Epub 2014 Jan 22.

36.

Community HIV-1 drug resistance is associated with transmitted drug resistance.

Tilghman MW, Pérez-Santiago J, Osorio G, Little SJ, Richman DD, Mathews WC, Haubrich RH, Smith DM.

HIV Med. 2014 Jul;15(6):339-46. doi: 10.1111/hiv.12122. Epub 2014 Jan 12.

37.

Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder.

Ellis RJ, Letendre S, Vaida F, Haubrich R, Heaton RK, Sacktor N, Clifford DB, Best BM, May S, Umlauf A, Cherner M, Sanders C, Ballard C, Simpson DM, Jay C, McCutchan JA.

Clin Infect Dis. 2014 Apr;58(7):1015-22. doi: 10.1093/cid/cit921. Epub 2013 Dec 18.

38.

An intervention study examining the effects of condom wrapper graphics and scent on condom use in the Botswana Defence Force.

Tran BR, Thomas AG, Vaida F, Ditsela M, Phetogo R, Kelapile D, Haubrich R, Chambers C, Shaffer R.

AIDS Care. 2014;26(7):890-8. doi: 10.1080/09540121.2013.860420. Epub 2013 Nov 22.

39.

Comparisons of reported sexual behaviors from a retrospective survey versus a prospective diary in the Botswana Defence Force.

Tran BR, Thomas AG, Vaida F, Ditsela M, Phetogo R, Kelapile D, Chambers C, Haubrich R, Shaffer R.

AIDS Educ Prev. 2013 Dec;25(6):495-507. doi: 10.1521/aeap.2013.25.6.495.

40.

Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.

Huang JS, Hughes MD, Riddler SA, Haubrich RH; Aids Clinical Trials Group A5142 Study Team.

HIV Clin Trials. 2013 Sep-Oct;14(5):224-34. doi: 10.1310/hct1405-224.

41.

Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.

Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, Fischl MA, Schackman BR, Riddler SA, Gulick RM.

Clin Infect Dis. 2013 Dec;57(11):1607-17. doi: 10.1093/cid/cit595. Epub 2013 Sep 17.

42.

Condom use behaviours and correlates of use in the Botswana Defence Force.

Tran BR, Thomas AG, Ditsela M, Vaida F, Phetogo R, Kelapile D, Chambers C, Haubrich R, Shaffer R.

Int J STD AIDS. 2013 Nov;24(11):883-92. doi: 10.1177/0956462413486889. Epub 2013 Jul 19.

43.

Virologic correlates of anti-CMV IgG levels in HIV-1-infected men.

Gianella S, Morris SR, Tatro E, Vargas MV, Haubrich RH, Daar ES, Dube MP, Richman DD, Little SJ, Smith DM.

J Infect Dis. 2014 Feb 1;209(3):452-6. doi: 10.1093/infdis/jit434. Epub 2013 Aug 20.

44.

Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation.

Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J, Riddler S, Tebas P, Zolopa AR, Collier AC, Brown TT.

Clin Infect Dis. 2013 Nov;57(10):1483-8. doi: 10.1093/cid/cit538. Epub 2013 Aug 13.

45.

Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence.

Blumenthal J, Haubrich R.

Expert Opin Pharmacother. 2013 Sep;14(13):1777-85. doi: 10.1517/14656566.2013.812072. Epub 2013 Jun 26. Review.

46.

Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men.

Gianella S, Smith DM, Vargas MV, Little SJ, Richman DD, Daar ES, Dube MP, Zhang F, Ginocchio CC, Haubrich RH, Morris SR; CCTG 592 Team.

Clin Infect Dis. 2013 Aug;57(3):441-7. doi: 10.1093/cid/cit252. Epub 2013 Apr 17.

47.

Biceps skin-fold thickness may detect and predict early lipoatrophy in HIV-infected children.

Innes S, Schulte-Kemna E, Cotton MF, Zöllner EW, Haubrich R, Klinker H, Sun X, Jain S, Edson C, van Niekerk M, Innes ER, Rabie H, Browne SH.

Pediatr Infect Dis J. 2013 Jun;32(6):e254-62. doi: 10.1097/INF.0b013e3182814b30.

48.

High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study.

Innes S, Cotton MF, Haubrich R, Conradie MM, van Niekerk M, Edson C, Rabie H, Jain S, Sun X, Zöllner EW, Hough S, Browne SH.

BMC Pediatr. 2012 Nov 23;12:183. doi: 10.1186/1471-2431-12-183.

49.

Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1.

Carlson JM, Brumme CJ, Martin E, Listgarten J, Brockman MA, Le AQ, Chui CK, Cotton LA, Knapp DJ, Riddler SA, Haubrich R, Nelson G, Pfeifer N, Deziel CE, Heckerman D, Apps R, Carrington M, Mallal S, Harrigan PR, John M, Brumme ZL; International HIV Adaptation Collaborative.

J Virol. 2012 Dec;86(24):13202-16. doi: 10.1128/JVI.01998-12. Epub 2012 Oct 10.

50.

Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals.

Krishnan S, Schouten JT, Atkinson B, Brown T, Wohl D, McComsey GA, Glesby MJ, Shikuma C, Haubrich R, Tebas P, Campbell TB, Jacobson DL.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):381-9. doi: 10.1097/QAI.0b013e3182690e3c.

Supplemental Content

Loading ...
Support Center